|Application ||IHC-P, WB, E|
|Other Accession||Q6AYR4, NP_001127902.1, NP_569726.2|
|Calculated MW||35714 Da|
|Antigen Region||194-221 aa|
|Other Names||Torsin-2A, Torsin family 2 member A, Torsin-related protein 1, TOR2A, TORP1|
|Target/Specificity||This TOR2A antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 194-221 amino acids from the Central region of human TOR2A.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||TOR2A Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Cellular Location||Endoplasmic reticulum lumen.|
|Tissue Location||Isoform 1 is expressed ubiquitously, except in cardiac and endothelial tissues.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Salusins are multifunctional bioactive peptides discovered by bioinformatics analyses of a full-length cDNA library. Salusin alpha and salusin beta are related peptides of 28 and 20 amino acids that were recently characterized. These peptides are considered to be biosynthesized from preprosalusin, an alternative-splicing product of the torsion dystonia-related gene (TOR2A), after frameshift reading and digestion at dibasic amino acids. Salusin alpha has recently been shown to be involved in atherosclerosis; it potently suppresses acyl-CoA:cholesterol acyltransferase-1 which stores cholesterol ester converted from free cholesterol in macrophages, thereby reducing human macrophage foam cell formation.
O'Farrell, C.A., et al. Neuroscience 164(3):1127-1137(2009)
Sato, K., et al. Peptides 29(12):2203-2207(2008)
Watanabe, T., et al. Hypertens. Res. 31(3):463-468(2008)
Wang, Z., et al. Eur. J. Pharmacol. 539(3):145-150(2006)
Humphray, S.J., et al. Nature 429(6990):369-374(2004)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.